Literature DB >> 28697187

Can semiquantitative measurements of SUVmax and cut-off values differentiate colorectal malignant from benign lessions?

Tram Nguyen1, Søren Hess, Henrik Petersen, Abass Alavi, Poul Flemming Høilund-Carlsen.   

Abstract

OBJECTIVE: We investigated maximum standardized uptake value (SUVmax) and cut-off values for differentiation of malignant and benign lesions in colorectal cancer (CC) as multiple studies have questioned their validity. We also investigated more extended indices using common semi-quantification analysis in incidental colorectal findings (ICF). SUBJECTS AND METHODS: Fluorine-18-fluoro deoxy glucose positron emission tomography/computed tomography in 25 patients with a total of 30 focal ICF was retrospectively analysed using dedicated software. Method variability was tested through application of three common threshold-based lesion delineation techniques as well as a partial-volume correction (PVC). Lesion SUVmax, SUVmean, metabolically active volume (MAV) and mean total lesion glycolysis (TLG) were thereby extracted along with PVC corrected values (cSUVmean, cTLG) and SUVpeak.
RESULTS: In all lesions, SUVmax was >5 and SUVmean≥2.7. Malignant SUVmax values (mean±SD: 16.5±6.2) were overall significantly higher than benign levels (9.8±3.6). There was a substantial overlap with values in polyps/adenomas (14.4±7.7). Both SUVpeak and SUVmean showed similar characteristics. Malignant MAV and TLG showed more distinct levels. Though different segmentation methods introduced variations, largest in MAV (-58.6%-141.5%), and PVC generally increased measures significantly by a factor of 1.2-2.7, neither changed relative levels much. SUVmax values were inadequate for aetiological differentiation of ICF, which also precludes a clinically significant cut-off value. The same applies to SUVpeak and SUVmean while TLG measures may be more indicative.
CONCLUSION: Semi-quantitative measurements of SUVmax and cut-off values proved inadequate for differentiating colorectal malignancies from benign findings. While integrated measures, e.g. cTLG, are potentially better indicators of disease severity and extent, more optimal segmentation and PVC methods are required.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28697187     DOI: 10.1967/s002449910551

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  3 in total

1.  Arginine ADP-ribosyltransferase 1 Regulates Glycolysis in Colorectal Cancer via the PI3K/AKT/HIF1α Pathway.

Authors:  Wen-Bo Long; Xia Pu; Yi Tang; Ming Li; Yun Liu; Qin She; Ya-Lan Wang; Qin-Xi Guo
Journal:  Curr Med Sci       Date:  2022-07-07

2.  Dual-time-point PET/CT study protocol can improve the larynx cancer diagnosis.

Authors:  Agata Karolina Pietrzak; Joanna Kazmierska; Andrzej Marszalek; Pawel Golusinski; Aleksandra Heydrych; Katarzyna Wiechec; Witold Cholewinski
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

3.  Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies.

Authors:  Agata Pietrzak; Andrzej Marszałek; Jolanta Kunikowska; Tomasz Piotrowski; Adrianna Medak; Katarzyna Pietrasz; Julia Wojtowicz; Witold Cholewiński
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.